Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
During the last three months, 5 analysts shared their evaluations of Capricor Therapeutics (NASDAQ:CAPR), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 4 | 1 | 0 | 0 | 0 |
Last 30D | 2 | 1 | 0 | 0 | 0 |
1M Ago | 1 | 0 | 0 | 0 | 0 |
2M Ago | 0 | 0 | 0 | 0 | 0 |
3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $30.6, a high estimate of $40.00, and a low estimate of $8.00. Observing a 27.5% increase, the current average has risen from the previous average price target of $24.00.
A clear picture of Capricor Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Aydin Huseynov | Ladenburg Thalmann | Raises | Buy | $25.00 | $24.00 |
Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $8.00 | - |
Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $40.00 | - |
Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $40.00 | - |
Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $40.00 | - |
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Capricor Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Capricor Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Capricor Therapeutics displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 1159.3%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -6.3%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Capricor Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.32% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -1.59%, the company showcases effective utilization of assets.
Debt Management: Capricor Therapeutics's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CAPR